These findings suggest that a feedforward cycle may exist in the TME, whereby VV-αCEA TCE treatment induces IFNγ production, elevating CEA levels and sensitizing CEA-positive tumour cells to TCE therapy. The gene discussed is IFNG; the disease is neoplasm.